Post Hoc Analysis of the GRIFFIN Trial Presented at ASCO 2022

Dr. Cesar Rodriguez Presents Post Hoc Analysis of Sustained MRD Negativity (GRIFFIN Trial) in TE NDMM Patients 

Abstract Title:

Daratumumab (DARA) + lenalidomide, bortezomib, and dexamethasone (RVd) in transplant-eligible newly diagnosed multiple myeloma (NDMM): A post hoc analysis of sustained minimal residual disease (MRD) negativity from GRIFFIN.

What is the purpose of this trial? 

To determine if the addition of daratumumab to lenalidomide-bortezomib-dexamethasone (RVd) will increase the proportion of participants achieving stringent complete response (sCR), as defined by the International Myeloma Working Group (IMWG) criteria, by the time of completion of post autologous stem cell transplantation (ASCT) consolidation treatment, compared with RVd alone. This is a post hoc analysis of sustained MRD negativity (median follow-up, 38.6 months) in the same subgroups and in patients with ≥ complete response (CR).

In this video:

Dr. Cesar Rodriguez (Mount Sinai Tisch Cancer Institute—New York, NY) presents a post hoc analysis of sustained MRD negativity (GRIFFIN Trial) using daratumumab (DARA) + lenalidomide, bortezomib, and dexamethasone (RVd) in transplant-eligible newly diagnosed multiple myeloma (TE NDMM) patients.

Conclusion:

Minimal residual disease (MRD) data in the GRIFFIN Trial show that the addition of Dara to RVd induction/consolidation and lenalidomide (R) maintenance may lead to durable MRD-negativity (10–5) rates in TE NDMM patients with high cytogenetic risk, ISS stage III, and those who achieve ≥ complete response (CR) or stringent complete response (sCR). However, larger studies are needed.

Clinical trial information: NCT02874742